BRINAVESS®
Vernakalant Hydrochloride 20 mg/ml
Therapeutic Indication:
BRINAVESS is indicated in adults for rapid conversion of recent onset atrial fibrillation to sinus rhythm:
- For non-surgery patients: atrial fibrillation ≤ 7 days duration.
- For post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration.
- Composition: Vernakalant Hydrochloride 20 mg/ml.
- Pharmaceutical Form: Concentrate for Solution for Infusion.
- Method of Administration: Intravenous.
- How Supplied: Single Vial of 10 ml (200 mg) or 25 ml (500 mg).
- Manufacturer: Correvio International Sarl, Switzerland.